Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
BravoBio took part in Bionetwork Asia 2011 in Singapore
Sept. 1, 2011
 
BravoBio's President, Dr. Wu Ke, was invited to give a solo presentation about the new version of Chinese GMP in the conference. Also as a panelist, he discussed with other delegates about how to bridge the cultural divide between East and West in global partnerships. More than 60 executives from Asia, Europe, Pacific and US came to the event.
 
BravoBio is setting up a JV with Chinese Academy of Sciences
Sept. 13, 2011
 
BravoBio signed an agreement with Institute of Virology, Chinese Academy of Sciences, to set up a Joint-venture this September. As the dominant shareholder of JV, BravoBio will help this institute to further develop its biotech projects as per requirements of SFDA and holds the right to pilot scale and large scale production and final commercialization.
 
China will improve epidemic vaccine system
Oct. 28, 2011
 
China will spend $1.45 billion to develop a national vaccine provision system to improve its ability to cope with epidemic emergencies. The goal is to create a system that can supply vaccines for regular use and that has the capacity to cope with epidemics. Officials say the system should be set up by 2015 and expect it will accommodate "major epidemic situations as quickly and effectively as those found in developed countries" 5 years later, according to Xinhuanet. It will provide not only increased vaccine production capacity but also improved epidemic monitoring and additional R&D.
 
China prepares for entry into world vaccine market
Nov. 30, 2011
 
China has 30 vaccine manufacturers capable of producing 1 billion vaccine doses annually. In March the World Health Organization ruled that China's State Food and Drug Administration regulation met international standards, opening the door for Chinese vaccine developers. These vaccine manufacturers will be upgrading their facilities as they prepare to begin exporting their low-cost vaccines to the rest of the world. China-based vaccine makers are preparing to compete with Western rivals for a slice of the $25.3 billion worldwide vaccine market. China's entrance into this market will be a major force of competition for Big Pharma companies that are accustomed to bigger profit margins.
 
A big step towards vaccine business by Takeda
Dec. 6, 2011
 
Takeda Pharmaceutical, the Japanese largest drug-maker, announces it will set up a Vaccine Business Division early next year targeting to enhance the company's capability of expanding its existing vaccine business on a global base. Takeda has already been a key supplier of pediatric vaccines for over 60 years. Several projects have been conducted to reveal the company's recent efforts in the vaccines area and those projects include Hib vaccine, a Sabin-inactivated poliovirus (s-IPV) vaccine, influenza vaccine and HPV vaccine.
 
Trial of Chikungunya Vaccine starts
Dec. 20, 2011
 
Scientists from National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health is going to conduct a clinical trial of an experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes. The vaccine was developed by researchers at the Vaccine Research Center (VRC) of NIAID using non-infectious virus-like particle technology (VLP) to induce an immune response. The purpose of the trial is to examine the vaccine's safety and ability to elicit antibodies against chikungunya virus.
 
Large-scale trials of Breast cancer vaccine
Jan. 19, 2012
 
The Cancer Vaccine Development Program at the San Antonio Military Medical Center has developed a breast cancer vaccine and early this year, large-scale clinical trials will begin. This therapeutic vaccine is designed to spur immune attacks on HER2-driven cancers and its rights were obtained by Galena Biopharma. Also, the company, which is based in Portland, OR, announced in November last year that it is collaborating with Genentech on a mid-size trial testing NeuVax together with Herceptin, the Genentech's blockbuster breast cancer drug.
 
BravoBio visited NHRI and potential collaborations discussed
Feb. 20, 2012
 
On Feb 12~14, 2012, Dr. Wu Ke, BravoBio, visited National Health Research Institutes located in Miaoli County, Taiwan. Dr. Wu had broad talking about biological projects with scientists of NHRI. Potential collaborations could be anticipated based on mutual interests.
 
Tuberculosis vaccine study got fund from Gates Foundation
Mar. 15, 2012
 
The Bill & Melinda Gates Foundation has committed up to $220 million grant through 2016 to Aeras, a nonprofit organization, supporting its large-scale efficacy trials for several mid- and early-stage TB vaccine candidates.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next